Overview
Good Clinical Practice Trainings are the essential foundation for all professionals involved in clinical research. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials that involve human subjects. Compliance with GCP ensures that the rights, safety, and well-being of trial participants are protected, and that clinical trial data are credible and reliable. The recent adoption of the ICH E6(R3) guideline in January 2025 represents a significant modernization of GCP principles, emphasizing risk-based, proportionate approaches and the integration of digital technologies. This guide provides a comprehensive overview of GCP training requirements and the programs available to help you stay compliant.
Why GCP Trainings Are Essential for Clinical Research Professionals
GCP Trainings are not just a regulatory requirement; they are a fundamental component of conducting ethical and high-quality clinical research. Key reasons why GCP training is essential include:
- Protecting Participant Rights and Safety – ensuring informed consent and ethical conduct
- Ensuring Data Integrity – maintaining accurate and reliable trial data
- Achieving Regulatory Compliance – meeting requirements of Health Canada, FDA, EMA, and other agencies
- Facilitating Global Trial Acceptance – enabling mutual recognition of trial data across jurisdictions
- Promoting Quality by Design – integrating quality into trial planning and conduct
As of April 1, 2026, Health Canada has implemented the ICH E6(R3) guideline, making updated GCP training mandatory for all clinical trial personnel in Canada.
Key Regulatory Frameworks Covered in GCP Trainings
Comprehensive GCP Trainings cover multiple regulatory frameworks, including:
- ICH E6(R3) – the global standard for GCP, including 11 fundamental principles and Annexes on interventional trials and decentralized/pragmatic elements
- Health Canada Part C, Division 5 – Canadian regulations for clinical trials involving human subjects
- FDA Regulations (21 CFR Parts 50, 56, 312, 314) – US requirements for informed consent, IRBs, INDs, and NDAs
- ICH E8(R1) – General Considerations for Clinical Studies, which complements E6(R3)
Detailed Course Breakdown
Course 1: Good Clinical Practices (ICH E6(R3) Focused)
This comprehensive training program provides an in-depth exploration of the ICH E6(R3) Good Clinical Practice guideline, the globally recognized standard for the ethical and scientific quality of clinical trial design, conduct, and reporting.
Scope: The curriculum is structured to guide participants through the entire guideline, covering the 11 fundamental principles, the expanded roles and responsibilities of sponsors and investigators, rigorous data governance frameworks, and the critical requirements for essential records. Participants will gain a thorough understanding of how to apply the new principles-based framework to ensure participant protection, data integrity, and regulatory compliance across diverse trial designs.
Description of Modules: The curriculum covers:
- ICH E6(R3) overview and its significance in global clinical research
- 11 Fundamental Principles of GCP and their application
- Sponsor responsibilities including oversight and quality management
- Investigator responsibilities including delegation and supervision
- Informed consent requirements and documentation
- Data governance and integrity frameworks
- Essential records and Trial Master File requirements
- Safety reporting and pharmacovigilance obligations
- Risk-based approaches to trial management
- Digital technologies and decentralized trial elements
Target Audience:
- Clinical Investigators and Sub-Investigators
- Sponsor Personnel (Medical, Regulatory, Clinical Operations)
- Clinical Research Associates (Monitors)
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Quality Assurance and Compliance Staff
- Clinical Trial Coordinators and Site Staff
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Clinical Research Organization (CRO) Personnel
Pricing: $149.00 with group discounts available.
FAQ:
- What is the relationship between ICH E6(R3) and other ICH guidelines? ICH E6(R3) forms an interconnected framework with ICH E8(R1) for trial design, ICH E9 for statistics, and ICH E2 for safety data management.
- How does ICH E6(R3) address decentralized clinical trials? ICH E6(R3) includes specific Annex provisions for decentralized and pragmatic trial elements, recognizing the growing importance of these trial models.
- What are the 11 fundamental principles of GCP? The 11 fundamental principles cover the ethical and scientific foundation of clinical trials, including participant safety, data integrity, and quality management.
- Why is ICH E6(R3) considered a modernization of GCP? It emphasizes risk-based, proportionate approaches and integrates digital technologies, moving away from a one-size-fits-all approach to trial management.
- Is ICH E6(R3) training mandatory for clinical trial personnel? Yes, ICH E6(R3) is the global standard for GCP, and training on this guideline is mandatory for all personnel involved in clinical research.
Enroll Now: https://www.gxptrainings.com/courses/ich-e6r3-good-clinical-practices-gcp/
Course 2: Health Canada Good Clinical Practice Training
This comprehensive training program provides clinical research professionals with the knowledge and practical skills required to conduct clinical trials in compliance with Health Canada Food and Drug Regulations (Part C, Division 5) and the ICH E6(R3) GCP guideline.
Scope: The curriculum is aligned with Health Canada’s adoption of ICH E6(R3) effective April 1, 2026. It covers Health Canada regulatory requirements, sponsor and Qualified Investigator responsibilities, clinical trial application processes, informed consent, safety reporting, data governance, quality management, and inspection readiness.
Description of Modules: The curriculum covers:
- Health Canada regulatory requirements for clinical trials (Part C, Division 5)
- ICH E6(R3) GCP principles and Annex 1
- Sponsor, Qualified Investigator, and REB responsibilities
- Clinical trial application (CTA) and amendment processes
- Informed consent requirements and participant protection
- Safety reporting obligations (AEs, SAEs, SUSARs)
- Data governance and record-keeping requirements
- Quality management and risk-based monitoring
- Investigational product management and GMP compliance
- Clinical trial inspections and enforcement
Target Audience:
- Sponsors (commercial and non-commercial/academic)
- Qualified Investigators and Principal Investigators
- Sub-Investigators and clinical research staff
- Research Ethics Board (REB) members and administrators
- Clinical Research Coordinators and study site personnel
- Contract Research Organizations (CROs) and Service Providers
- Clinical monitors and auditors
- Regulatory affairs and quality assurance professionals
- Pharmacovigilance professionals and research nurses
Pricing: Competitive pricing with group discounts available.
FAQ:
- What is the deadline for updating GCP training to ICH E6(R3)? Health Canada implemented ICH E6(R3) on April 1, 2026. All clinical trial personnel should complete updated training to align with the new guideline.
- Is Health Canada GCP training recognized internationally? Yes, Health Canada GCP training is recognized globally as it aligns with ICH E6(R3), the international standard for GCP.
- What is the difference between a Qualified Investigator and a Principal Investigator? The Qualified Investigator is the legally defined role under Health Canada regulations, while Principal Investigator is a broader term used in clinical research.
- What are the requirements for informed consent under Health Canada? Informed consent must be obtained from all participants before trial participation, with documentation in accordance with Part C, Division 5 requirements.
- What is the role of the Research Ethics Board (REB) in Health Canada regulations? The REB provides ethical oversight and review of clinical trials, ensuring participant protection.
Enroll Now: https://www.gxptrainings.com/courses/health-canada-good-clinical-practice-training/
Course 3: HIPAA Clinical Data Privacy, Security & Compliance Training
This training program provides organizations and individuals with a comprehensive understanding of the legal, regulatory, and operational requirements for protecting health information in clinical research and healthcare delivery settings.
Scope: The program covers the full spectrum of privacy, security, and compliance obligations under U.S. federal law and international good practice standards. It includes protection of Protected Health Information (PHI) and Electronic Protected Health Information (ePHI), HIPAA Privacy, Security, and Breach Notification Rules, Good Clinical Practice (GCP) under ICH E6(R3), and security controls for information systems.
Description of Modules: The curriculum covers 10 comprehensive sections:
- HIPAA Overview and regulatory landscape
- HIPAA Privacy Rule requirements and PHI protections
- HIPAA Security Rule requirements and ePHI safeguards
- HIPAA Breach Notification Rule requirements
- GCP and clinical data integrity requirements
- Security controls for information systems and cloud environments
- Regulatory compliance frameworks including FDA, NIST, and ISO
- Incident management and breach response
- Risk assessment methodologies
- Roles and responsibilities of Sponsors, CROs, Investigators, and vendors
Target Audience:
- Covered Entities under HIPAA
- Business Associates and their subcontractors
- Clinical Research Professionals, including Sponsors, CROs, Principal Investigators, and IRBs
- Security and Compliance Professionals
Pricing: $249.00 with group discounts available.
FAQ:
- What is the difference between PHI and ePHI? PHI (Protected Health Information) is health information that identifies an individual, while ePHI is PHI that is created, stored, or transmitted electronically.
- What is the HIPAA Breach Notification Rule? It requires covered entities and business associates to notify affected individuals, the HHS, and in some cases the media, following a breach of unsecured PHI.
- How does HIPAA relate to GCP? HIPAA protects participant privacy in clinical research, while GCP ensures the ethical and scientific quality of trials. Both are essential for clinical trial compliance.
- What is the role of a Business Associate under HIPAA? A Business Associate is a person or entity that performs certain functions or activities involving PHI on behalf of a covered entity.
- How often should HIPAA training be renewed? It is recommended to complete HIPAA training annually to stay current with regulatory updates and enforcement trends.
Enroll Now: https://www.gxptrainings.com/courses/hipaa-clinical-data-privacy-security-compliance-training/
Course 4: GCP Global Auditor Certification Program
This training program defines the complete knowledge and performance requirements for personnel involved in clinical research to become certified global auditors for Good Clinical Practice (GCP).
Scope: The program integrates GCP requirements from ICH E6(R3), Health Canada Part C, Division 5, and FDA regulations (21 CFR Parts 50, 56, 312, 314.50, and 314.80) with auditing practices based on ISO 19011:2026 for internal, second-party (vendor/CRO/site audits), and global regulatory compliance auditing. The participant learns what GCP requires under multiple regulatory frameworks, how to audit those requirements, and how to conduct audits across multiple jurisdictions.
Description of Modules: The curriculum covers:
- Regulatory Frameworks including ICH E6(R3), Health Canada Division 5, and FDA 21 CFR Parts 50, 56, 312, 314
- Auditing Practices based on ISO 19011:2026 including seven auditing principles
- Audit programme management including objectives, risks, and resources
- Conducting an audit from initiation to follow-up
- Remote auditing methods including virtual audits and security considerations
- Competence and evaluation of auditors
- Second-party auditing including supplier qualification and vendor audits
Target Audience:
- Quality Assurance Personnel
- Clinical Research Associates (Monitors)
- Study Directors and Clinical Trial Managers
- Clinical Investigators and Site Staff
- Sponsor Personnel
- CRO Personnel
- IRB/IEC Members and Coordinators
- Data Management and Biostatistics Professionals
- Pharmacovigilance and Safety Specialists
- Regulatory Affairs Professionals
- Audit Program Managers
Pricing: $499.00 with group discounts available.
FAQ:
- What are the prerequisites for the GCP Global Auditor Certification? Completion of basic GCP awareness training of at least four hours or equivalent on-the-job experience, plus at least six months of experience in clinical research.
- What is ISO 19011:2026 and why is it important for auditors? ISO 19011:2026 provides guidelines for auditing management systems, covering audit principles, programme management, conduct, remote methods, and competence evaluation.
- What are the seven principles of auditing? The seven principles are integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- What regulatory frameworks are covered in this program? The program covers ICH E6(R3), Health Canada Part C Division 5, and FDA 21 CFR Parts 50, 56, 312, 314.50, and 314.80.
- Can I conduct regulatory inspections with this certification? No, the program is designed for global auditing across internal, second-party, and regulatory readiness contexts and does not qualify individuals to conduct regulatory inspections on behalf of authorities.
Enroll Now: https://www.gxptrainings.com/courses/gcp-global-auditor-certification-program/
Course 5: Certified Regulatory Affairs Professional (CRAP)
This comprehensive certification program provides regulatory professionals with end-to-end knowledge of the global pharmaceutical regulatory landscape. The program covers the complete drug development lifecycle from discovery through post-approval lifecycle management, with specific focus on the regulatory requirements of the United States (FDA), European Union (EMA), and Japan (PMDA), as well as harmonization initiatives under ICH.
Scope: The program is structured to provide both foundational regulatory knowledge and advanced strategic capabilities across all major application types, including Investigational New Drug (IND) applications, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Biologics License Applications (BLA), Orphan Drug Designation, and Special Programs including Accelerated Approval and Breakthrough Therapy.
Description of Modules: The curriculum covers:
- Global Regulatory Framework overview
- Investigational New Drug (IND) applications
- New Drug Applications (NDA) for innovative pharmaceuticals
- Abbreviated New Drug Applications (ANDA) for generics
- Biologics License Applications (BLA) for biological products
- Orphan Drug Designation for rare disease treatments
- Special Programs including Accelerated Approval and Breakthrough Therapy
- Post-approval lifecycle management
- Regulatory agency interactions and meeting management
- Global regulatory strategy development
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- CRO and CMO Personnel
- Legal and Intellectual Property Professionals
Pricing: $799.00 with group discounts available.
FAQ:
- What is the difference between an IND and an NDA? An IND (Investigational New Drug) application is submitted to authorize clinical trials, while an NDA (New Drug Application) is submitted to obtain marketing approval for a new drug.
- What is the eCTD format and why is it important? eCTD (Electronic Common Technical Document) is the standard format for regulatory submissions, enabling efficient review and global harmonization of submission requirements.
- What is the purpose of an Orphan Drug Designation? Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases, providing incentives such as market exclusivity and tax credits.
- What is the role of ICH in global drug development? ICH develops guidelines that harmonize regulatory requirements across regions, facilitating efficient global drug development.
- What are the key elements of a Biologics License Application (BLA)? A BLA includes manufacturing information, nonclinical studies, clinical data, and labeling for biological products.
Enroll Now: https://www.gxptrainings.com/courses/certified-regulatory-affairs-professional/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Authors
